Alberto Costa, MD Appointed Chief Medical Advisor for Dune Medical Devices Europe
FRAMINGHAM, Mass., Jan. 10, 2012 /PRNewswire/ — Dune Medical Devices announced today the appointment of Dr. Alberto Costa to the position of Chief Medical Advisor for Dune Medical Devices Europe. Costa is internationally renowned as an expert in breast cancer care, and widely known for innovative ideas in educational development in his role as Director of the European School of Oncology. A specialized breast surgeon at Professor Veronesi’s school in Milan, Costa is Executive Director of the Southern Switzerland Breast Unit in Lugano and Breast Cancer Scientific Coordinator at the Multimedica Group in Milan, Italy. He is a member of the international panel of experts of the St. Gallen Guidelines Conference.
“Dr. Costa is a widely-respected, highly accomplished breast surgeon, who brings clinical and educational expertise, as well as established relationships with organizations and institutions across Europe. We believe that his expertise in all aspects of breast cancer treatment will strengthen our ability to reach and train surgeons on the use of the MarginProbe® System,” said Dan Levangie, CEO of Dune Medical Devices. “In this role, we will work with Dr. Costa to develop our Medical Education program to enable surgeons throughout Europe to improve their ability to remove cancer in a single surgery.”
Dr. Costa, Editor-in-chief of the journal The Breast, and the author of more than 250 scientific publications, said, “In the treatment of breast cancer, we have long awaited a technology which could help improve our ability to remove cancer in one surgery. MarginProbe represents a unique breakthrough for surgeons everywhere. Given the critical nature of margins, I am excited about leading the effort to improve breast cancer surgery in Europe.”
About the MarginProbe System
The MarginProbe System enables real time detection of cancer at or near the surface of excised tissue specimens during surgery for breast cancer. The simple and immediate assessment of the surgical margins allows surgeons to immediately excise additional tissue, potentially saving a second procedure.
The MarginProbe System is Dune’s first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device in the U.S.
About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.
Dune Medical Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, Germany and Switzerland. For more information, please visit www.dunemedical.com
Contact: Michael Graffeo, Dune Medical Devices, Michael.firstname.lastname@example.org, (508) 620-2782
SOURCE Dune Medical Devices